Table 4 Summary of cost estimates (studies with an incident and mixed approach are underlined)
From: Cost-of-illness studies in heart failure: a systematic review 2004–2016
Reference | Year of cost data | Country | Reported annual costs in local currency (costs per patient) | Local currency in 2016 | $US (2016 PPP) | % of inpatient costs of all direct costs | Expenditure on health, per capita, US$ (2016 PPP) |
|---|---|---|---|---|---|---|---|
Voigt, 2014 [35] | 2012 | USA | $60.2 - $115.4ba(direct costs) $70.8 - $127.0ba(total costs) | $62.9 - $120.7ba $74.0 - $133.0ba | 62.9–120.7ba 74.0–133.0ba | 66 | 9892 |
Czech, 2013 [36] | 2010 | Poland | 7739 PLN | 8312 PLN | 4755 | 92e | 1798 |
Delgado, 2013 | 2010 | Spain | 4860€ (healthcare costs) | 5166€ | 7792 | 58e | 3248 |
Bogner, 2010 [24] | 2009 | USA | 22,230$b | 24,873$b | 24,873b | 84 | 9892 |
Zugck, 2010 [30] | 2002 | Germany | 11,794–16,303 €c | 14,297–19,762 €c | 18,472–25,532c | 72 | 5551 |
Neumann, 2009 [29] | 2006 | Germany | 2.879b €a | 3.293b €a | 4.255ba | 60 | 5551 |
Liao, 2007 [23] | 2006 | USA | $10,832 | 12,907$ | 12,907 | 65e | 9892 |
Agvall, 2005 [28] | 2000 | Sweden | 37,060 SEK | 44,971 SEK | 5044 | 47 | 5488 |
Stafylas, 2016 | 2014 | Greece | 4411 € | 4295 € | 7053 | 73e | 2223 |
Ogah, 2014 [32] | 2010 | Nigeria | 2128$ | 2343$ | 2343 | 44 | NA |
Lee, 2016 [31] | 2016 | South Korea | 868$ (perspective of third-party-payer) 1414$ (perspective of society) | 868$ 1414$ | 868 1414 | 53 | NA |
Dunlay, 2011 [34] | 2007 | USA | 109.541$ (lifetime costs from HF diagnosis until death) | 126.819$ | 126.819 | 77 | 9892 |
Corrao, 2014 [33] | 2011 | Italy | 11,100 € | 11,597 € | 15,952 | 92e | 3391 |
Liao, 2006 [25] | 2000 | USA | 32,580–33,023$ (prevalent group)d 45,604–49,128$ (incident group)d | 45,406–46,023$d 63,557–68,468$d | 45,406–46,023d 63,557–68,468d | 65–67 70–72 | 9892 |
Ory, 2005 [26] | 2000 | USA | 14,465$ (prevalent group) 17,744$ (incident group) | 20,159$ 24,729$ | 20,159 24,729 | NA | 9892 |
Murphy, 2016 | 2013 | Ireland | 12,206 € (patients with preserved EF) 13,011 € (patients with reduced EF) | 12,194 € 12,999 € | 15,334 16,330 | 92e 96e | 5528 |